

Haematologica
HAEMATOL/2016/163246
Version 4

Lenalidomide/Melphalan/Dexamethasone in newly diagnosed patients
with AL Amyloidosis: results of a prospective phase 2 study with
long-term follow-up

Ute Hegenbart, Tilmann Bochtler, Axel Benner, Natalia Becker,
Christoph Kimmich, Arnt V. Kristen, Jörg Beimler, Ernst Hund, Markus
Zorn, Anja Freiberger, Marianne Gawlik, Hartmut Goldschmidt, Dirk
Hose, Anna Jauch, Anthony D. Ho, and Stefan O. Schönland

Disclosures: U.H.: Travel grant (Janssen) S.O.S.: Travel grant (Janssen, Medac, Binding Site), consultancy (Prothema, Janssen), research funding (Janssen) D.H.: Travel grant (Takeda), consultancy (Celgene), Research funding (EngMab) A.S.: Travel grant (Takeda), Research funding (EngMab) H.G: Research Support: Celgene, Janssen, Chugai, Novartis, BMS, Millennium; Advisory Boards: Janssen, Celgene, Novartis, Onyx, Amgen Takeda, BMS; Honoraria: Celgene, Janssen, Novartis, Chugai, Onyx, Millennium The other authors declare no conflict of interest.

Contributions: S.O.S. and U.H. wrote the paper. A.B. and N.B. were responsible for statistical analysis. S.O.S., T.B., C.K., A.V.K., J.B., E.H., M.G., and U.H. took care of the patients. M.Z. was responsible for the laboratory examinations. A.J. performed cytogenetic analyses. S.O.S., T.B. H.G., A.D.H., A.F. and U.H. designed research.